clinical trial · NCT06496243
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NewAmsterdam Pharma·phase2·recruiting·n = 69
Dyslipidemiasobicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
brief summary
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
started
Dec 2, 2024
primary completion
Nov 1, 2026
completion
Feb 1, 2027
last updated
Apr 9, 2026
official title
A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol